Zogenix hands GW a win
A phase III Lennox-Gastaut trial sees Fintepla meet statistical significance but fail the test of clinical relevance.
Go or no go? Esperion's double whammy and a look to priority reviews
Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
Genmab is seeking data to position tisotumab as its first in-house launch, while Zogenix wants Fintepla to challenge GW in Lennox-Gastaut syndrome.
Zogenix gets an unwelcome distraction from Fintepla
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.
GW sets its sights on Zogenix and a new Epidiolex use
A strong pivotal result should allow the company to broaden Epidiolex’s reach to tuberous sclerosis complex, as long as liver injury risk can be ruled out.
Zogenix’s pain is GW Pharma’s gain
A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.
GW’s Dravet lock looks broken as Zogenix data scores
Battle in a rare form of epilepsy queued up following positive phase III trial.
Upcoming events – Zogenix and Mallinckrodt look to rare diseases
Zogenix and Mallinckrodt face investor scrutiny as they report critical data that will answer questions about safety and efficacy.
